Optellum

An Oxford company whose AI helps doctors decide which lung nodules on a scan are most likely to be cancer.

About Optellum

Optellum develops AI tools for lung cancer diagnosis. Its Lung Cancer Prediction AI helps clinicians find and prioritise high-risk lung nodules, and its Virtual Nodule Clinic supports the follow-up process. It is also building LungOS, an AI platform for chest care. A June 2026 release says it is used at more than 250 clinical sites.

Chief executive Dr Johnathan Watkins said the company wants "ensuring early diagnosis and early intervention become the standard for everyone everywhere".

Optellum is headquartered in Oxford, UK, with an office in Houston, Texas. The June 2026 release shows it is still trading.

We did not find a description of the culture, values or headcount, and the only person named was the chief executive.

The release lists no vacancies and we found no graduate scheme, internship or apprenticeship. Check Optellum's own careers page; AI, software, imaging and clinical skills all matter in this kind of company.

What they do

• {'desc': 'Helps rank how risky a lung nodule is.', 'title': 'Lung Cancer Prediction AI'}
• {'desc': 'Supports follow-up of patients with lung nodules.', 'title': 'Virtual Nodule Clinic'}
• {'desc': 'A platform for chest and lung care that it is building.', 'title': 'LungOS'}

Key facts

• Headquartered in Oxford, UK; office in Houston, USA
• Used at more than 250 clinical sites (June 2026)
• CEO: Dr Johnathan Watkins
• Release dated 5 June 2026

Website: optellum.com